Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials-Reference-Cited by-同舟云学术

Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials

Published:2023-09 Issue: Volume:119 Page:102601
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Castellano Grazia,Corti Chiara^ORCID,Boldrini Laura,Gervaso Lorenzo,Criscitiello Carmen,Curigliano Giuseppe

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference28 articles.

1. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline;Tew;J Clin Oncol,2020

2. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann Oncol,2021

3. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Parker;Ann Oncol,2020

4. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer;Golan;N Engl J Med,2019

5. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Ledermann;Ann Oncol,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS);Expert Opinion on Drug Safety;2024-08-12

2. Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-06

3. Exploring the utility and limitations of ChatGPT in scientific literature searches;ESMO Real World Data and Digital Oncology;2023-11